Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
Mult Scler
; 28(7): 1155-1159, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1861991
ABSTRACT
INTRODUCTION:
Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry. CASE SERIES We report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild.DISCUSSION:
These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Neuromyelitis Optica
/
COVID-19
/
BNT162 Vaccine
/
Multiple Sclerosis
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Mult Scler
Journal subject:
Neurology
Year:
2022
Document Type:
Article
Affiliation country:
13524585211049737
Similar
MEDLINE
...
LILACS
LIS